Halozyme Therapeutics Earns Place in the Prestigious Russell 1000 Index

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a leading biopharmaceutical firm, has recently been added to the Russell 1000® Index, effective after market close on June 27, 2025. This influential index comprises approximately 1,000 of the largest securities in the U.S., categorized by market capitalization, making it a critical benchmark for investors tracking the performance of large-cap stocks.

Dr. Helen Torley, President and CEO of Halozyme, emphasized the significance of this inclusion as a pivotal moment for the company. She stated, "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth." Halozyme's strategy focuses on increasing visibility with investors as it aims to deliver sustainable growth and profitability well into the future.

The Russell 1000 Index, managed by FTSE Russell, serves a vital role in the financial markets, offering a comprehensive view of large-cap U.S. equities. It provides investors with a trusted performance measure while enhancing the profile of companies within its ranks. Membership lasts for one year and is contingent upon a company's standing in the broader Russell 3000® Index.

Halozyme, headquartered in San Diego, California, specializes in innovative solutions designed to enhance patient outcomes and experiences in drug delivery. The company is notable for its ENHANZE® technology, which utilizes a proprietary enzyme known as rHuPH20 to facilitate the subcutaneous delivery of various injected medications. This technology aims to streamline the treatment processes, reducing patient burdens and improving efficiency in healthcare settings.

Having positively impacted over one million lives, Halozyme’s technology is employed across ten commercialized products in multiple regions worldwide. The company has partnered with major pharmaceutical firms such as Roche, Takeda, Pfizer, AbbVie, and more, showcasing its extensive reach and collaborative spirit in the industry.

Moreover, Halozyme develops drug-device combination products that incorporate advanced auto-injector technologies, aiming to deliver significant advantages in convenience and patient comfort. These initiatives underline Halozyme’s commitment to innovation within healthcare, especially as it continues to seek partnerships and product development opportunities.

As Halozyme approaches this new chapter in its corporate journey, the company remains focused on executing its strategic objectives and enhancing its contribution to the biopharmaceutical landscape. The recognition by the Russell 1000 Index not only validates Halozyme’s achievements but also sets the stage for continued expansion and influence in the industry.

By leveraging its innovative approaches and partnerships, Halozyme Therapeutics positions itself as a key player in improving drug delivery systems, ultimately benefiting patients and healthcare providers alike. As the company furthers its mission, investors look forward to its sustained growth and the valuable solutions it brings to the market.

For anyone interested in learning more about Halozyme Therapeutics and its pioneering work, additional information is available at www.halozyme.com, along with updates via their LinkedIn and Twitter pages.

It's an exciting time for Halozyme, with vast potential for growth and advancements in biotechnology to look forward to, reinforcing the importance of their inclusion in the prestigious Russell 1000 Index.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.